Pharmacologic treatment of body dysmorphic disorder

Primary Psychiatry

Volumn 13, Issue 7, 2006, Pages 61-69

  Hadley, Sallie Jo ^a,c   Kim, Suah ^b   Priday, Lauren ^a   Hollander, Eric ^c  

^a Department of Psychiatry ^*  (United States)

^b Compulsive and Impulsive Disorders Program ^*  (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; CYPROHEPTADINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; BEHAVIOR THERAPY; BODY DYSMORPHIC DISORDER; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; EATING DISORDER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMPULSE CONTROL DISORDER; LIBIDO DISORDER; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; STOMACH DISCOMFORT; SUBSTANCE ABUSE;

EID: 33746238167     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Phillips KA. Pharmacologic treatment of body dysmorphic disorder. Psychopharmacol Bull. 1996;32(4):597-605.
2. Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry. 2001;62(9):721-727.
3. Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. CNS Spectr. 2002;7(6):453-460,463.
4. Fallon BA. Pharmacotherapy of somatoform disorders. J Psychosom Res. 2004;56(4):455-460.
5. Phillips KA, Coles ME, Menard W, Yen S, Fay C, Weisberg RB. Suicidal ideation and suicide attempts in body dysmorphic disorder. J Clin Psychiatry. 2005;66(6):717-725.
6. Allen A, Hollander E. Body dysmorphic disorder. Psychiatr Clin North Am. 2000;23(3):617-628.
7. Sondheimer A. Clomipramine treatment of delusional disorder-somatic type. J Am Acad Child Adolesc Psychiatry. 1988;27(2):188-192.
8. Hollander E, Liebowitz MR, Winchel R, Klumker A, Klein DF. Treatment of body-dysmorphic disorder with serotonin reuptake blockers. Am J Psychiatry. 1989;146(6):768-770.
9. Phillips KA, McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry. 1993;150(2):302-308.
10. Goetz KL, Price TR. A case of Koro: treatment response and implications for diagnostic classification. J Nerv Ment Dis. 1994;182(10):590-591.
11. Kizu A, Miyoshi N, Yoshida Y, Miyagishi T. A case with fear of emitting body odour resulted in successful treatment with clomipramine. Hokkaido Igaku Zasshi. 1994;69(6):1477-1480.
12. Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol. 1996;11(4):247-254.
13. Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59(4):165-171.
14. Hollander E, Allen A, Kwon J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56(11):1033-1039.
15. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59(4):381-388.
16. Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64(6):715-720.
17. Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006;21(3):177-179.
18. Heimann SW. SSRI for body dysmorphic disorder. J Am Acad Child Adolesc Psychiatry. 1997;36(7):868.
19. Grant JE, Phillips KA. Recognizing and treating body dysmorphic disorder. Ann Clin Psychiatry. 2005;17(4):205-210.
20. Rosen JC, Reiter J, Orosan P. Cognitive-behavioral body image therapy for body dysmorphic disorder. J Consult Clin Psychol. 1995;63(2):263-269.
21. Erratum in: J Consult Clin Psychol. 1995;63(3):437.
22. Neziroglu F, Khemlani-Patel S. A review of cognitive and behavioral treatment for body dysmorphic disorder. CNS Spectr. 2002;7(6):464-471.
23. Saxena S, Winograd A, Dunkin JJ, et al. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder. J Clin Psychiatry. 2001;62(1):67-72.
24. DeMarco LM, Li LC, Phillips KA, McElroy SL. Perceived stress in body dysmorphic disorder. J Nerv Ment Dis. 1998;186(11):724-726.
25. Castle DJ, Molton M, Hoffman K, Preston NJ, Phillips KA. Correlates of dysmorphic concern in people seeking cosmetic enhancement. Aust N Z J Psychiatry. 2004;38(6):439-444.
26. Phillips KA, Pagano ME, Menard W, Fay C, Stout RL. Predictors of remission from body dysmorphic disorder: a prospective study. J Nerv Ment Dis. 2005;193(8):564-567.
27. Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2003;6(4):317-323.
28. Phillips KA, Dufresne RG. Body dysmorphic disorder. A guide for dermatologists and cosmetic surgeons. Am J Clin Dermatol. 2000;1(4):235-243.
29. Phillips KA, Pagano ME, Menard WE, Fay C, Stout RL. A prospective longitudinal investigation of the course of body dysmorphic disorder (BDO) and pharmacotherapy received. Neuropsychopharmacology. 2004;29(suppl):S200-S201.
30. Waldinger MO, Olivier B. Selective serotonin reuptake inhibitor-induced sexual dysfunction: clinical and research considerations. Int Clin Psychopharmacol. 1998;13(suppl 6):S27-S33.
31. Gitlin MJ, Suri R, Altshuler L, Zuckerbrow-Miller J, Fairbanks L. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J Sex Marital Ther. 2002;28(2):131-138.
32. Munro A. Monosymptomatic hypochondriacal psychosis. Br J Psychiatry Suppl. 1988;(2):37-40.
33. Phillips KA. Body dysmorphic disorder: the distress of imagined ugliness. Am J Psychiatry. 1991;148(9):1138-1149.
34. Carroll BJ, Yendrek R, Degroot C, Fanin H. Response of major depression with psychosis and body dysmorphic disorder to ECT. Am J Psychiatry. 1994;151(2):288-289.
35. Phillips KA, Kim JM, Hudson JI. Body image disturbance in body dysmorphic disorder and eating disorders. Obsessions or delusions? Psychiatr Clin North Am. 1995;18(2):317-334.
36. Zimmerman M, Mattia JI. Body dysmorphic disorder in psychiatric outpatients: recognition, prevalence, comorbidity, demographic, and clinical correlates. Compr Psychiatry. 1998;39(5):265-270.
37. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
38. Capstick N. Depressive reactions in the course of clomipramine therapy used in the treatment of obsessional conditions. Scott Med J. 1975;20(1 suppl):45-48.
39. Vargel S, Ulusahin A. Psychopathology and body image in cosmetic surgery patients. Aesthetic Plast Surg. 2001;25(6):474-478.
40. Nierenberg AA, Phillips KA, Petersen TJ, et al. Body dysmorphic disorder in outpatients with major depression. J Affect Disord. 2002;69(1-3):141-148.
41. Aski R, Cilli AS. Body dysmorphic disorder in psychiatric outpatients: diagnosis, other psychiatric diagnosis, demographic and clinical correlates [Turkish]. Turk Psikiyatri Derg. 2002;13(3):197-203.
42. Rotenberg KJ, Taylor D, Davis R. Selective mood-induced body image disparagement and enhancement effects: are they due to cognitive priming or subjective mood? Int J Eat Disord. 2004;35(3):317-332.
43. Phillips KA, Stout RL. Associations in the longitudinal course of body dysmorphic disorder with major depression, obsessive-compulsive disorder, and social phobia. J Psychiatr Res. 2006;40(4):360-369.
44. Winokur G, Black DW, Nasrallah A. Depressions secondary to other psychiatric disorders and medical illnesses. Am J Psychiatry. 1988;145(2):233-237.
45. Brawman-Mintzer D, Lydiard RB, Phillips KA, et al. Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry. 1995;152(11):1665-1667.
46. McKay D, Todaro J, Neziroglu F, Campisi T, Moritz EK, Yaryura-Tobias JA. Body dysmorphic disorder: a preliminary evaluation of treatment and maintenance using exposure with response prevention. Behav Res Ther. 1997;35(1):67-70.
47. Phillips KA, Diaz SF. Gender differences in body dysmorphic disorder. J Nerv Ment Dis. 1997;185(9):570-577.
48. Phillips KA, Menard W, Fay C, Weisberg R. Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder. Psychosomatics. 2005;45(4):317-325.
49. Grant JE, Kim SW, Crow SJ. Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. J Clin Psychiatry. 2001;62(7):517-522.
50. Phillips KA, McElroy SL, Hudson JI, Pope HG Jr. Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? J Clin Psychiatry. 1995;56(suppl 4):41-51; discussion 52.
51. Phillips KA, Menard W, Pagano ME, Fay C, Stout RL. Delusional versus nondelusional body dysmorphic disorder: clinical features and course of illness. J Psychiatr Res. 2006;40(2):95-104.
52. Elmer KB, George RM, Peterson K. Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Am Acad Dermatol. 2000;43(4):683-686.
53. Weintraub E, Robinson C. A case of monosymptomatic hypochondriacal psychosis treated with olanzapine. Ann Clin Psychiatry. 2000;12(4):247-249.
54. Chaichan W. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. Psychiatry Clin Neurosci. 2004;58(4):364-368.
55. Phillips KA, Siniscalchi JM, McElroy SL. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatr Q. 2004;75(4):309-320.
56. Coles ME, Phillips KA, Menard W, et al. Body dysmorphic disorder and social phobia: cross-sectional and prospective data. Depress Anxiety. 2006;23(1):26-33.
57. McElroy SL, Phillips KA, Keck PE Jr. Obsessive compulsive spectrum disorder. J Clin Psychiatry. 1994;55 (suppl):33-51.
58. Dufresne RG, Phillips KA, Vittorio CC, Wilkel CS. A screening questionnaire for body dysmorphic disorder in a cosmetic dermatologic surgery practice. Dermatol Surg. 2001;27(5):457-462.
59. Phillips KA, Gunderson CG, Mallya G, McElroy SL, Carter W. A comparison study of body dysmorphic disorder and obsessive-compulsive disorder. J Clin Psychiatry. 1998;59(11):568-575.
60. Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv. 2003;54(8):1111-1118.
61. Frare F, Perugi G, Ruffolo G, Toni C. Obsessive-compulsive disorder and body dysmorphic disorder: a comparison of clinical features. Eur Psychiatry. 2004;19(5):292-298.
62. Grant JE, Kim SW, Eckert ED. Body dysmorphic disorder in patients with anorexia nervosa: prevalence, clinical features, and delusionality of body image. Int J Eat Disord. 2002;32(3):291-300.
63. Wildes JE, Simons AD, Marcus MD. Bulimic symptoms, cognitions, and body dissatisfaction in women with major depressive disorder. Int J Eat Disord. 2005;38(1):9-17.
64. Ruffolo JS, Phillips KA, Menard W, Fay C, Weisberg RB. Comorbidity of body dysmorphic disorder and eating disorders: severity of psychopathology and body image disturbance. Int J Eat Disord. 2006;39(1):11-19.
65. Phillips KA, Taub SL. Skin picking as a symptom of body dysmorphic disorder. Psychopharmacol Bull. 1995;31(2):279-288.
66. O'Sullivan RL, Phillips KA, Keuthen NJ, Wilhelm S. Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine. Psychosomatics. 1999;40(1):79-81.
67. Wilhelm S, Keuthen NJ, Deckersbach T, et al. Self-injurious skin picking: clinical characteristics and comorbidity. J Clin Psychiatry. 1999;60(7):454-459.
68. Grant JE, Menard W, Pagano ME, Fay C, Phillips KA. Substance use disorders in individuals with body dysmorphic disorder. J Clin Psychiatry. 2005;66(3):309-316.
69. Lepola U, Koponen H, Leinonen E. Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiatry. 1994;27(5):186-188.
70. Kosieradzki PH. Citalopram in social phobia. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1126-1127.
71. Jefferson JW. Social anxiety disorder: more than just a little shyness. Prim Care Companion J Clin Psychiatry. 2001;3(1):4-9.
72. Phillips KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162(2):377-379
73. Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162(5):1022-1023.
74. Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull. 1996;32(1):175-180.
75. Smith WT, Londborg PD, Glaudin V, Painter JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry. 1998;155(10):1339-1345.
76. Wada T, Kawakatsu S, Nadaoka T, Okuyama N, Otani K. Clomipramine treatment of delusional disorder, somatic type. Int Clin Psychopharmacol. 1999;14(3):181-183.
77. Neziroglu F, Yaryura-Tobias JA. A review of cognitive behavioral and pharmacological treatment of body dysmorphic disorder. Behav Modif. 1997;21(3):324-340.
78. McKay D. Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder. Behav Modif. 1999;23(4):620-629.
79. Phillips KA. Body dysmorphic disorder: diagnosis and treatment of imagined ugliness. J Clin Psychiatry. 1996;57(suppl 8):61-64.
80. Barr LC, Goodman WK, Price LH. Acute exacerbation of body dysmorphic disorder during tryptophan depletion. Am J Psychiatry. 1992;149(10):1406-1407.